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Abstract:  1 
Aging is one of the major risk factors of osteoarthritis. This pathology during which chondrocytes undergo 2 
modifications of their phenotype may result from alteration of TGFβ signaling. This study investigates the role of 3 
TGFß response in process of chondrocyte dedifferentiation/redifferentiation.  4 
Dedifferentiation was induced by successive passages of human articular chondrocytes, whereas their 5 
redifferentiation was performed by tridimensionnal culture in alginate. Human mesenchymal stem cells were 6 
obtained from bone marrow and differentiated into chondrocyte-like phenotype by 3D-culture, embedded in the same 7 
scaffold. Protein and mRNA levels were analyzed by Western-Blot and real time RT-PCR. Regulatory mechanism 8 
was investigated using specific inhibitors (mithramycin), mRNA silencing or decoy oligonucleotides, and expression 9 
vectors.  10 
Chondrocyte dedifferentiation interfered with TGFß signalling by decreasing TßRII mRNA and protein levels and 11 
subsequent TGFβ response. TßRII ectopic expression in passaged chondrocytes permitted to increase the expression 12 
of several matrix genes, such as aggrecan or type II collagen. Redifferentiation of passaged chondrocytes permitted 13 
to restore, at least in part, TßRII expression, and was related to differentiation of human bone marrow mesenchymal 14 
stem cells toward chondrocytes, where both Sp1 and TßRII mRNA levels were increased. Moreover, Sp1 15 
manipulation by silencing or ectopic expression and pharmacologic inhibition revealed a link between expression 16 
levels of this transcriptional factor, which is crucial for constitutive expression of TβRII in cartilage, and TGFß 17 
response.  18 
Therefore, these data permit us to suggest an important role of TßRII expression in maintenance of chondrocyte 19 
phenotype, which is altered with age, and bring new insights in our understanding of chondrogenesis process. 20 
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INTRODUCTION 1 
Articular cartilage consists of an abundant extracellular matrix, which is produced by chondrocytes. These highly 2 
differentiated cells are responsible for the maintenance of the cartilage as a functional entity. Aging cause changes in 3 
the properties of this tissue, notably by modifying the matrix composition or the growth factor responsiveness 4 
(Kempson,1982 ; Thonar et al., 1986 ; Dozin et al., 2002;  Loeser et al., 2000; Rosen et al., 1997; Guerne, et al., 5 
1995). During embryonic development, cartilage formation is initiated with condensation of mesenchymal cells, 6 
followed by progression of chondrocyte differentiation toward proliferation, prehypertrophy and hypertrophy. 7 
During osteoarthritis (OA), an articular disease strongly correlated with ageing (Buckwalter and Mankin, 1998, van 8 
der Kraan et van den berg, 2008), chondrocytes undergo morphogenic alterations accompanied by profound 9 
biochemical changes including the loss of production of cartilage-specific macromolecules. For instance, type II 10 
collagen expression decreased wheareas type I collagen synthesis increases. Some of the alterations of chondrocyte 11 
phenotype can be reproduced in vitro. Passages induce morphogenic alterations of cells, reduction of type II 12 
collagen, and induction of type I collagen synthesis (Benya et al., 1978; Archer et al., 1990; Pei et al., 2000; 13 
McDougall et al., 1996, Homicz et al., 2002). However, this model is not able to mimic others modifications 14 
undergone by OA chondrocytes, and notably the induction of type X collagen, specific of hypertrophy stage. On the 15 
other hand, the chondrocyte-specific phenotype can be recovered when the cells are cultured in three-dimensional 16 
culture system, such as alginate matrices (Reginato et al., 1994 ; Bonaventure et al., 1994).  17 
Several studies suggest that modifications of chondrocyte phenotype during OA result from alteration of 18 
Transforming Growth Factor β (TGFβ) signaling. Thus, the expression of TGFβ and its signaling molecules is 19 
altered with age, and the subsequent lack of TGFβ responsiveness might be at the root of OA development (Blaney-20 
Davidson et al., 2005). Besides, TGFβ signaling is important for chondrogenesis. It promotes the differentiation of 21 
embryonic chick limb cartilage (Schonherr et al., 2000), and upregulates a number of molecules associated with 22 
prechondrogenic condensation (Serra et al., 1997; Chimal-Monroy et al., 1999; Grimaud et al., 2002). In addition, 23 
primary chondrogenesis derived from mesenchymal stem cells (MSCs) needs TGFß signals (Reddi, 1994; 24 
Andriamanalijaona et al., 2008).  25 
Members of TGFß family transduce their signal via two serine/threonine receptors, type I (TßRI) and type II (TßRII) 26 
receptors (Wrana et al., 1994). Upon ligand-binding, TßRI is phosphorylated by TßRII, resulting in activation of 27 
intracellular proteins, named Smads. Receptor-regulated Smads (R-Smads: Smad2 and Smad3) are phosphorylated 28 
by TßRI. Phosphorylated R-Smads form heterodimers with common-partner Smad (Co-Smads: Smad4), and 29 
translocate into the nucleus where they bind to specific DNA sequences for activation of TGFß target gene 30 
transcription (Shi et al., 2003). Inhibitory Smads (I-Smads: Smad7) inhibit phosphorylation of R-Smads by 31 
competing with their binding to activated TßRI (Nakao et al., 1997). Recently, it was shown that besides signaling 32 
via TßRI (Activin-like kinase 5, ALK5), TGF-beta can also signal via ALK1, thereby activating Smad1/5/8 instead 33 
of Smad2/3 (Blaney-Davidson et al., 2009; Finnson et al., 2008). 34 
We hypothesised that the maintenance of chondrocyte phenotype, which is altered with age, required a functional 35 
TGFβ signalling. We examined the influence of members of TGFß signalling on chondrocyte phenotype. We 36 
showed that TßRII is implicated in the loss of TGFß responsiveness observed during chondrocytes passages. TßRII 37 
 4 
ectopic expression permits to restore TGFß responsiveness as well as to increase the expression of some matrix 1 
components. We also found that TβRII expression level is intimately linked to differentiation status of chondrocytes. 2 
Finally, we established a relationship between TGFβ-induced effects on matrix genes, and expression level of 3 
Specific protein 1 (Sp1) transcription factor, which expression is decreased in the course of dedifferentiation process 4 
(Duval et al., 2011) and is require to ensure constitutive expression of TβRII in chondrocytes (Baugé et al., 2008). 5 
 6 
 7 
MATERIAL AND METHODS 8 
Reagents. 9 
Reagents were supplied by Invitrogen (Fisher Bioblock Scientific, Illkirch, France) unless otherwise noted. 10 
Mithramycin (Sigma-Aldrich, St. Quentin Fallavier, France) and TGFß1 (R&D Systems, Lille, France) were 11 
resuspended in PBS or PBS-HCl, respectively. Alginate was provided by Sigma-Aldrich, and oligonucleotides were 12 
supplied by Eurogentec (Angers, France). 13 
 14 
Chondrocyte culture  15 
Human articular chondrocytes (HAC) were prepared from femoral head of post-mortem individuals with no known 16 
joint diseases or after femoral head fractures (ages between 45 and 80 years with median age of 68). The causes of 17 
donor’s death were multiple and all of them signed agreement forms in the context of a body donation program 18 
according to local legislations. Similarly, donors from arthroscopy signed the agreement for this study according to 19 
local ethical comitee (CPP). Chondrocytes were released by enzymatic digestion as previously described (Baugé et 20 
al., 2007). Cells were seeded at 4x104 cells/cm2 and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (4.5 21 
g⁄L D-glucose) supplemented with 10% heat-inactivated foetal calf serum (FCS), 100 IU/ml penicillin, 100 µg/ml 22 
streptomycin and 0.25 µg/ml fungizone, in a 5 % CO2 atmosphere. For dedifferentiation, HAC were passaged up to 23 
five times (P5) (about 7-8 population doubling)  with trypsin-EDTA after reaching confluency. 24 
For re-differentiation studies, chondrocytes, which had underwent three passages (about 4-5 population doubling), 25 
were encapsulated in alginate beads. Cells were suspended in alginate at the density of 2.5x106 cells/ml, then slowly 26 
dropped into a 100 mM CaCl2 solution. After instantaneous gelation, the beads were allowed to polymerize further 27 
for a period of 10 min in CaCl2 solution. After three washes in PBS, they were finally placed in DMEM 28 
supplemented with 10% foetal calf serum. After 3 weeks, the beads were rinsed with PBS and dissolved in a solution 29 
composed of 55 mM sodium citrate and 25 mM EDTA. The suspension was incubated at 37°C until the beads were 30 
completely dissolved (approximately 10 min.). Centrifugation of the suspension at 800 g for 10 min allows 31 
separating the cells from their alginate matrix.  32 
 33 
Culture of human bone marrow-derived stem cells  34 
Human bone marrow-derived stem cells were collected from the same patients as donors used for HAC isolation. 35 
The harvested cells were washed twice with α-MEM, and isolated by adherence over 24h to tissue culture plastic and 36 
were expanded in monolayer culture with α-MEM supplemented with glutamine, FGF (1 ng/ml), 10% FCS and 37 
 5 
antibiotics. After amplification by successive passages (until P5), the absence of hematopoietic markers (such as 1 
CD45) was checked by RT-PCR (data not shown). Thereafter, bone marrow-derived stem cells were directed toward 2 
chondrogenesis by culture in 3-D scaffold (alginate bead). 3 
For chondrogenic differentiation, isolated human bone marrow derived stem cells were encapsulated in alginate 4 
beads, according to the same protocol than HAC, and cultured with a chondrogenic medium consisting of DMEM 5 
containing 100 nM dexamethasone, 50 µg/ml ascorbic acid-2-phosphate, 40 µg/ml proline, 1mM sodium pyruvate 6 
and Insulin Transferin Selenium supplement (ITS, Sigma), for 21 days and the media were changed twice a week.   7 
 8 
Plasmids and transfection experiments 9 
p3TPLux, pCMV5-TßRII, pEVR2-Sp1 expression vectors were described earlier (Baugé et al., 2008). Chondrocytes 10 
were transiently transfected by the calcium phosphate precipitation method as previously described (Baugé et al., 11 
2007). After overnight transfection, the culture medium was replaced by DMEM containing 10% FCS, and 12 
maintained in culture for 24 h.  13 
 14 
Luciferase assay  15 
Luciferase assay was performed with Luciferase Assay kit from Promega (Charbonnières, France), as previously 16 
described  (Baugé et al., 2007). 17 
 18 
Gene silencing experiments 19 
1.5 µg of double strand siRNA targeting Sp1, provided from Santa-Cruz Biotechnology (through Tebu, Le Perray en 20 
Yvelines, France), were nucleofected in HAC, according to the manufacturer’s protocol with human chondrocyte 21 
Nucleofector solution (Amaxa, Köln, Germany). Negative control siRNA known to not lead to specific degradation 22 
of any cellular message was also used. After 6 h of transfection, the culture medium was replaced with DMEM 23 
containing 10% FCS and the chondrocytes cultures were incubated for 24 h. 24 
 25 
RNA extraction and real-time RT-PCR.  26 
Total RNA from primary HAC cultures were extracted using Trizol. Following extraction, 1 µg of DNase-I treated 27 
RNA was reverse transcribed into cDNA in the presence of random hexamers (Applied Biosystems, Courtaboeuf, 28 
France) and Moloney murine leukaemia virus reverse transcriptase. The reaction was carried out at 37°C for 1h 29 
followed by a further 10-min step at 95°C. Amplification of the generated cDNA was performed by real-time PCR in 30 
Applied Biosystems SDS7000 apparatus with appropriate primers designed with Primer Express software. The 31 
relative mRNA level was calculated with the 2-∆∆CT method. 32 
 33 
Protein extraction and Western-blot.  34 
Cells were rinsed, scrapped in RIPA lysis buffer supplemented with phosphatase and protease inhibitors. The 35 
extracts (30 µg protein) were subjected to fractionation in a 8 or 10% SDS-PAGE, transferred to PVDF membranes 36 
(Amersham Biosciences, Orsay, France), and reacted with rabbit aggrecan, TβRII or Sp1 polyclonal antibodies. 37 
 6 
Subsequently, membranes were incubated with anti-rabbit secondary peroxidase-conjugated antibody. The signals 1 
were revealed with SuperSignal West Pico Chemiluminescent Substrate (Pierce Perbio Science, Brébières, France) 2 
and exposed to X-ray film. The membranes were also reacted with anti β-actin to verify equal loading.  3 
 4 
Synthesis and transfection of decoy oligonucleotides.  5 
Sp1 decoy oligonucleotides sequences are:  Forward 5‘- ATTCGATCGGGGCGGGGCGAGC -3' and Reverse 5’- 6 
CGACGCCCCGCCCCGATCGAAT -3’ (consensus sequences are underlined). This decoy oligonucleotide was 7 
previously shown to bind Sp1 transcriptional factor (Baugé et al., 2008). These oligonucleotides were annealed 8 
overnight and transfected into cells using the Oligofectamine reagent according to the manufacturer’s instructions.  9 
 10 
Nuclear extracts and EMSA 11 
Nuclear extracts were prepared as described previously (Dignam et al., 1983). For EMSA, 5 fentomoles of (γ-12 
32P)ATP-labelled probes (Sp1 binding sequence) and 4 µg of nuclear extracts were incubated at room temperature 13 
for 15 min in binding buffer (20 mM Tris-HCl pH 7.5, 1 mM DTT, 100 mM NaCl, 5% bovine serum albumin, 0.1% 14 
Nonidet P-40, 10% glycerol, 25 µM ZnCl2) and 2 µg of poly(dI-dC).(dI-dC). Samples were resolved on native 15 
polyacrylamide gel and exposed for autoradiography. 16 
 17 
Statistical analysis: 18 
All experiments were repeated at least with 3 different donors, and similar results were obtained. Representative 19 
experiments are shown in the figures. Data are presented as the mean + SD. Statistical significance was determined 20 
by Student’s t-test. P values less than 0.05 were considered significant. ***= P <0.001;**= P < 0.01; *= P < 0.05 21 
versus controls. 22 
 23 
24 
 7 
RESULTS 1 
Chondrocyte passages reduce the TGFß responsiveness and decrease TßRII expression. 2 
In order to ascertain that subculturing chondrocytes led to the loss of cartilaginous phenotype in our hands, we 3 
monitored the decrease of type II collagen and aggrecan mRNA expression after successive passages. Their 4 
expressions were strongly decreased as soon as the first passage (about 2 cell doubling). The maximal reduction was 5 
obtained at P2 (approximatively 3 doubling) and was maintained at least until P5. At opposite, collagen type I and III 6 
mRNA levels were higher at P2 (suppl figure 1A). Therefore, we limited the following experiments to 2 or 3 7 
passages (3-5 cell doubling). 8 
To investigate chondrocyte responsiveness to TGFß during dedifferentiation process, we focused on the expression 9 
of Plasminogen Activator Inhibitor-1 (PAI-1), which is rapidly induced by TGFβ in chondrocytes (Baugé et al., 10 
2007). Human articular chondrocytes which underwent three passages were incubated for 4 h with TGFβ1 (2 ng/ml). 11 
Figure 1A shows that passages induced a significant decrease of PAI-1 induction by TGFß.   12 
TGFß initiates its cellular action by binding to TßRII, which in turn activates TßRI. Thus, we investigated the effect 13 
of passages on mRNA expression of both receptors. Whereas TßRI transcripts were increased in comparison to 14 
primary chondrocytes (P0) (fig. 1B), TβRII is dramatically decreased following dedifferentiation (fig. 1C). This 15 
reduction of TßRII expression was also observed at protein level (fig 1D). 16 
 17 
Passages increases the expression of the R-Smad, Smad3, and decreases that of the I-Smads, Smad7.  18 
Since signalling by TGFß is mediated by Smads, we explored the potential alteration of Smads expression during 19 
chondrocyte dedifferentiation. Our result (fig 2) showed that serial passages of chondrocytes in serum supplemented 20 
medium did not modulate significantly Smad2 and 4 mRNA levels. Moreover, they increased Smad3 mRNA levels 21 
whereas they decreased the expression of the I-Smad, Smad7. These data suggest that the loss of TGFß 22 
responsiveness observed in dedifferentiated chondrocytes is independent of Smads expression level, since an up-23 
regulation of Smad3 and down-regulation of Smad7 is usually associated with activation of TGFß signalling. 24 
 25 
Ectopic expression of TßRII restores TGFß responsiveness in passaged chondrocytes and increases expression 26 
of matrix genes. 27 
To confirm the crucial role of TßRII expression alteration in the reduction of TGFß sensitiveness of passaged 28 
chondrocytes, we examined the effect of forced TßRII expression on the induction of PAI-1 by TGFß (fig 3A). HAC 29 
were transfected with a TβRII expression vector (pCMV5-TβRII) or its corresponding insertless vector (pCMV5) for 30 
24h and further incubated with TGFβ. Dedifferentiation clearly causes reduced TGFβ-induced PAI-1 expression, 31 
which was restored by TβRII ectopic expression. In addition, transfection of TβRII expression vector in passaged 32 
chondrocytes induces an increased mRNA level the expression of aggrecan and collagen type II (x2-3) (fig 3B-C).  33 
 34 
TßRII expression increases during chondrocyte differentiation 35 
Since TßRII levels decreased upon dedifferentiation, we hypothesized that its expression could also be modulated 36 
during chondrocyte differentiation process. Therefore, we pursued by examination of TßRII expression in re-37 
differentiating chondrocytes. For that, the TßRII mRNA level was evaluated prior dedifferentiation (P0), after 38 
 8 
dedifferentiation (P3) and after redifferentiation in alginate. TßRII mRNA level was increased after a 3 week-culture 1 
in alginate (fig 4A), time which permit to restore (at least partially) a chondrocyte phenotype in this system (Duval et 2 
al., 2011). 3 
Similar experiments were performed using human bone marrow-derived mesenchymal stem cells, which underwent 4 
chondrogenesis by culture in alginate microbeads (Duval E/Boumediene K, unpublished data; suppl data 2B). This 5 
system is well-known to induce chondrogenic differentiation from mesenchymal stem cells from different origins 6 
(Andriamanalijaona et al., 2008). As shown in figure 4B, TßRII mRNA levels strongly increased with the culture 7 
time, and subsequently increased during differentiation of hBM derived-MSC into chondrocyte-like phenotype.  8 
 9 
Sp1 is important for TβRII expression and the maintenance of chondrocyte phenotype  10 
Given that Sp1 expression decreases during chondrocyte dedifferentiation and is restored by alginate culture (Duval 11 
et al., 2011), we proposed that Sp1 expression and activity could increase during differentiation of stem cells. Sp1 12 
mRNA level was raised during human bone marrow derived stem cells differentiation into chondrocytes (Fig 5A). 13 
To define whether DNA binding activity of Sp1 is also increased in these conditions, EMSAs were performed using 14 
the consensus DNA binding site as a probe (fig 5B). One delayed protein-DNA complex was strongly enhanced by 15 
hBM-MSC culture in alginate beads after 72h or 96h. The binding activity of the complex to the probe was 16 
decreased in the presence of Sp1 antibody (and not in the presence of irrelevant antibodies, namely against cKrox or 17 
Sp3), indicating that this complex contains Sp1 factor. 18 
Then, we investigated the effect of inhibition of Sp1 on TßRII expression. First, we blocked the binding activity of 19 
Sp1 family members using decoy oligonucleotides or mithramycin (Jia et al., 2007) and showed that the loss of Sp1 20 
binding to DNA inhibited TßRII mRNA level expression (fig 6A-B). Furthermore, we established that the specific 21 
reduction of Sp1 expression by RNA silencing, checked by Western-blot, reduced TßRII expression (fig 6C). 22 
Mithramycin also reduced TßRII protein expression. Interestingly, aggrecan expression was also decreased by 23 
mithramycin (figure 6D). 24 
Finally, in figure 7, we showed that Sp1 ectopic expression is able to restore TßRII expression in dedifferentiated 25 
chondrocytes and counteracts inhibition of aggrecan expression induced by passages. 26 
 27 
28 
 9 
DISCUSSION 1 
Modifications of chondrocyte phenotype occur with aging and during osteoarthritis. They can be mimicked, in part, 2 
in vitro by subculturing monolayer cultures of chondrocytes (Homicz et al., 2002; Pei et al., 2000; McDougall et al., 3 
1996; Duval et al., 2011). This culture model provides a way to understand some of the molecular mechanisms 4 
responsible for chondrocyte senescence and dedifferentiation, and to elucidate the transition from young/healthy to 5 
old/osteoarthritic cartilage. Conversely, studies of mechanism of re-differentiation of chondrocyte or differentiation 6 
of mesenchymal cells into chondrocytes can permit to bring new insights in order to develop the therapeutic use of 7 
mesenchymal stem cells (MSC) in cartilage disorders. In this study, we showed that chondrocyte dedifferentiation is 8 
accompanied by TßRII expression alteration, whereas redifferentiation of passaged chondrocytes or differentiation of 9 
MSC into chondrocytes are accompanied by TßRII production. Moreover, we demonstrated that forced TßRII 10 
expression is able to restore totally or partially the expression of matrix genes, suggesting a key-role of this receptor 11 
and TGFß signal in the maintenance of chondrocyte phenotype.  12 
Our in vitro experiments show the key-role of TßRII expression in chondrocyte phenotype maintenance. This result 13 
completes in vivo data which showed TßRII-deficient mice have a reduced proliferation of chondrocytes and an 14 
accelerated early hypertrophic differentiation relative to control (Seo et al., 2007). In addition, conditional transgenic 15 
mice in which a dominant negative form of TßRII is expressed, develop a hypoplastic cartilage (Hiramatsu et al., 16 
2011), confirming that TßRII is required for normal cartilage development, and subsequently chondrocyte 17 
phenotype.  18 
Chondrocyte dedifferentiation, which occurs with aging, is likely associated to alteration of cell responsiveness to 19 
TGFß by reduction of TßRII expression. Of interest, we have recently demonstrated that interleukin-1ß, a 20 
proinflammatory cytokine which is increased in OA process, rendered cells insensitive to TGFß by reducing TßRII 21 
expression (Baugé et al., 2007). Together, these results corroborate in vivo data, which indicated that TßRII 22 
expression is dramatically reduced in old mice (Blaney Davidson et al., 2005) and during OA (Boumediene et al., 23 
1998; Verdier et al., 2005), and confirmed the relationship between TßRII expression and the reduction of cell 24 
responsiveness to TGFß observed in OA and old cartilage. Concerning TßRI expression, it increases with passages, 25 
suggesting that this receptor is not involved in the reduction of cell responsiveness to TGFß in passaged 26 
chondrocytes. This result was unexpected since TßRI expression is reduced during experimental OA induced in mice 27 
by destabilization of the medial meniscus model (Blaney-Davidson et al., 2009). 28 
In addition, we examined the expression levels of TGFß signalling intracellular mediators, namely Smads. We 29 
showed that Smad3 expression is increased during chondrocytes dedifferentiation whereas that of Smad2 is not 30 
modified. Similar effects were obtained in vivo with aging (Blaney-Davidson et al., 2005). Smad3 acts as one 31 
important TGFß signalling pathway members to develop and/or maintain the phenotype of chondrocytes. Smad3, but 32 
not Smad2, stimulates primary chondrogenesis (Furumatsu et al., 2005). In addition, Smad3 deficiency accelerates 33 
chondrocytes maturation and leads to osteoarthritis (Yang et al., 2001; Van de Laar et al., 2011). Therefore, we 34 
speculate that the increased Smad3 expression observed during dedifferentiation and aging could be a compensatory 35 
mechanism to promote the chondrocyte phenotype. Moreover, these results obtained on Smad expression could be 36 
due to the loss of TGFß response since TGFß reduces Smad3 expression (Mori et al., 2000; Baugé et al., 2011). 37 
 10 
We also observed the TßRII expression during in vitro chondrogenesis. Three-dimensional scaffold was used to re-1 
differentiate dedifferentiated chondrocytes or to differentiate MSC toward chondrogenic phenotype. This culture 2 
system was described earlier to permit the induction of chondrogenic markers (Reginato et al., 1994; Bonaventure et 3 
al., 1994; Andriamanalijaona et al., 2008; Lemare et al., 1998; Cai et al., 2007; Duval et al., 2011). We showed that 4 
TßRII expression is induced during redifferentiation of subcultured chondrocytes and during chondrogenic process 5 
of stromal stem cells. In this regard, Mizuta and coll. found that expression of both TßRI and TßRII receptors was 6 
upregulated during periosteal chondrogenesis induced by exogenous TGFß1 treatment (Mizuta et al., 2002). Our data 7 
corroborate another in vitro study which proposes that TGFß signal transduction may be involved in the early stage 8 
of bone marrow-MSC chondrogenesis (Huang et al., 2005), and are consistent with recent studies, which 9 
demonstrated that TßRII down-regulation induced by retinoid acid treatment inhibits chondrogenesis of mouse 10 
embryonic palate mesenchymal cells (Yu et Xing, 2006) and that TGFß signalling is needed in the chondrogenic 11 
differentiation of MSC (Longobardi et al., 2006).  12 
Finally, we investigated the role of Sp1 role in the regulation of TßRII expression and matrix production. This 13 
ubiquitous zinc-finger protein has earlier been proposed to regulate matrix production by adult articular chondrocytes 14 
maintained in primary and expansion culture (Duval et al., 2011; Dharmavaram et al., 1997 ; Oh et al., 2007). 15 
Furthermore, we have demonstrated loss of Sp1 gene expression as a function of chondrocyte passage number and 16 
that Sp1 protein synthesis is restored in part by re-differentiation in 3D-alginate culture (Duval et al., 2011). Here, 17 
we showed that the decrease of Sp1 induced by serial passaging of chondrocytes is responsible for TßRII reduction. 18 
However, we cannot exclude that Sp1 acts indirectly. Sp1 might permit the re-expression of TßRII in 19 
dedifferentiated chondrocytes through Sox9, which can be induced by Sp1 (Piera-Velazquez et al., 2007). Sox9 was 20 
first identified as a transcription factor which specifies the chondrocyte lineage and is absolutely required for 21 
complete cartilage differentiation (Bi et al., 1999). In our study, Sp1 was not able to counteract the decrease of type 22 
II collagen (data not shown) whereas it increases aggrecan mRNA level in passaged chondrocytes. Since it was 23 
previously established that TßRII gene expression occurred earlier than that of type II collagen gene expression 24 
during differentiation of bone marrow-MSC under dynamic compressive loading (Huang et al., 2005), we 25 
hypothesize that longer time of Sp1 overexpression could restore the aggrecan or type II collagen expression in 26 
dedifferentiated chondrocytes. In order to validate this speculation, it will be necessary to reproduce this experiment 27 
using stable transfection system, which could permit to maintain a high level of Sp1 during a long period.  28 
In conclusion, we demonstrated that TßRII expression level is essential to maintain and/or promote chondrocyte 29 
phenotype, and established a key-role of Sp1 in this process. These findings may help in understanding the behaviour 30 
of aged chondrocytes. In addition, it brings original insights in the process of MSC differentiation into chondrocytes 31 
and subsequently permits to envisage innovative strategies to optimize the therapeutic use of chondrocytes or MSC 32 
in cartilage disorders.    33 
 34 
 35 
 36 
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FIGURE LEGENDS 1 
Figure 1: Chondrocyte passages reduces the TGFß responsiveness and decreases TßRII expression. 2 
A: Primary (P0 : about 1-2 population doubling) or passaged (P1 (~ 2-3 population doubling), P2 (~ 3-4 population 3 
doubling) and P3 (~ 4-5 population doubling)) HAC were cultured for 5-6 days before incubation with TGFβ1 (2 4 
ng/ml) for 4 h. Total RNA was isolated and analyzed by real-time RT-PCR, using PAI-1 and GAPDH primers. 5 
B-C: Total RNA and proteins from freshly isolated chondrocytes or from chondrocytes dedifferentiated by repeated 6 
passages were extracted. TßRI and TßRII mRNA levels were defined by real-time RT-PCR.  7 
D: TßRII protein level was analyzed by Western-blot.  8 
 9 
Figure 2: Passages up-regulates the R-Smad, Smad3, and down-regulates the I-Smads, Smad7.  10 
A-D: HAC were cultured as described in figure 1 and Smad2, 3, 4 and 7 mRNA levels were analyzed by real-time 11 
RT-PCR. Results are shown as histograms of relative expression versus GAPDH signal.  12 
 13 
Figure 3: Ectopic expression of TßRII restores TGFß responsiveness in passsaged chondrocytes and increases 14 
expression of matrix genes.  15 
A: Primary HAC (P0) or passaged twice (P2) were transfected with TβRII expression vector (pCMV5-TβRII) or 16 
with the insertless plasmid (5 µg). After 15 h, the medium was changed for DMEM+2% FCS for 24 h and cells were 17 
incubated with TGFβ1 addition (2 ng/ml) for 4 h. PAI-1 expression was analyzed by real-time RT-PCR. 18 
B-C: HAC were cultured and transfected as above. 24 h later, col2A1 and aggrecan mRNA expression was analyzed 19 
and normalized with GAPDH level (B). Aggrecan and TβRII protein levels were also analysed by Western-blot (C). 20 
 21 
Figure 4: TßRII expression increases during chondrocyte differentiation  22 
A: Primary chondrocytes (P0) or HAC dedifferentiated by 3 passages (P3) were cultured in monolayer or transferred 23 
into alginate beads for 21 days. Thereafter, TßRII mRNA level was analyzed by real-time RT-PCR. 24 
B: Human bone marrow-derived stem cells were cultured in alginate beads for different incubation-period and TßRII 25 
mRNA levels were assayed. Results are shown as relative gene expression versus GAPDH signal.  26 
 27 
Figure 5: Sp1 expression increases during chondrocyte differentiation 28 
A: Human bone marrow-derived stem cells were cultured in alginate beads for different incubation-period and Sp1 29 
mRNA levels were assayed. Results are shown as histograms of relative gene expression versus GAPDH signal.  30 
B: Electrophoretic mobility shift assay (EMSA) reactions were performed using probe corresponding to Sp1 31 
consensus DNA binding site, incubated with 4 μg nuclear extract from hBM-MSC cultured in alginate for 0h, 72h or 32 
96h. EMSA reactions were also performed after incubation of nuclear extracts (from hBM cultured 72h in alginate) 33 
with Sp1, Sp3 and cKrox antibodies. 34 
 35 
Figure 6: Sp1 regulates TβRII expression. 36 
 18 
A: Primary HAC, transfected with a Sp1 consensus binding sequence (Sp1 decoy), were incubated in DMEM+2% 1 
FCS for 24 h. Thereafter, TβRII mRNA versus GAPDH level was determined by RT-PCR. 2 
B: Subconfluent cultures of chondrocytes were treated for 48 h in the presence or absence of mithramycin (100 and 3 
150 nM). TβRII expression was analyzed at mRNA level by real-time RT-PCR. 4 
C: HAC were nucleofected with siRNA oligonucleotides targeted Sp1 or with control siRNA. Thereafter, the 5 
medium was replaced with DMEM+10% FCS for 24 h. Sp1 and TßRII protein levels were defined by Western-Blot. 6 
D: Chondrocytes were treated for 48 h in the presence or absence of mithramycin (100 and 150 nM). TβRII and 7 
aggrecan expression was analyzed at protein level by Western-Blot. 8 
 9 
Figure 7: Sp1 regulates chondrocyte phenotype   10 
A-B: HAC passaged twice (P2) were transfected with Sp1 expression vector (pEVR2-Sp1) or with the insertless 11 
plasmid (5 µg). After 15 h, the medium was changed for DMEM+2% FCS for 24 h. Total RNA was isolated and 12 
TßRII and aggrecan mRNA levels were analyzed and normalised with GAPDH level, in comparison to HAC with no 13 
passage (P0). 14 
 15 
Suppl data 1:  16 
Primary (P0) or passaged (until P5 ~ 6-7 population doubling) HAC were cultured in monolayer for 5-6 days. 17 
Thereafter, COL1A1, COL2A1, COL3A1 and aggrecan mRNA levels were analyzed by real-time RT-PCR. 18 
 19 
Suppl data 2: 20 
A: P3 (~ 4-5 population doubling) chondrocytes were cultured in monolayer or transferred into alginate beads for 21 21 
days. Thereafter, COL1A1, COL2A1, COL3A1 mRNA levels were analyzed by real-time RT-PCR. 22 
B: Human bone marrow-derived stem cells were cultured in alginate beads for 7 days and COL2A1 and aggrecan 23 
mRNA levels were assayed. Results are shown as histograms as relative gene expression versus GAPDH signal.  24 
 25 
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